Illumina, Inc. (ILU.DE)
Illumina, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $124.28, up 0.60% on the session, giving a market capitalisation of $18.80B. Its beta of 1.47 implies it has historically moved more than the broad market.
Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Illumina, Inc. is most often compared with the following Healthcare names: